Gilead Sciences to Present New HIV Treatment and Prevention Data at CROI 2026

Got story updates? Submit your updates here. ›

Gilead Sciences, Inc. announced it will present new clinical and real-world data from its HIV treatment and prevention portfolio at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, Colorado. The data will focus on expanding therapeutic options, including Phase 3 results from trials exploring an investigational single-tablet combination regimen and 96-week viral suppression results from a Phase 2 study evaluating islatravir plus lenacapavir.

Why it matters

As the HIV epidemic continues, there is an ongoing need to develop new and improved treatment and prevention options that can address the diverse needs of affected communities. Gilead's research aims to expand the toolkit available to healthcare providers and people living with HIV.

The details

Notable late-breaking abstracts include Phase 3 results from the ARTISTRY-1 and ARTISTRY-2 trials that explored the efficacy and safety of an investigational, single-tablet combination regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) in people living with HIV who are virologically suppressed and switched from their prior antiretroviral therapy. Additional research will expand scientific understanding of Gilead's exploratory HIV treatment combinations, including 96-week viral suppression results from a Phase 2 study evaluating islatravir plus lenacapavir, which has the potential to be the first weekly oral HIV treatment regimen.

• CROI 2026 will be held from February 22-25, 2026 in Denver, Colorado.

What’s next

Lenacapavir is being evaluated as a long-acting option in multiple ongoing and planned early and late-stage clinical studies in Gilead's HIV prevention and treatment research program.